Responders, N = 38 | |
---|---|
Cancer treatment | |
Already had taken oral chemotherapy | 13 (34) |
Knew about the choice between oral/intravenous | 8 (21) |
Knew the prescribed dose | |
Perfectly well | 11 (29) |
Relatively well | 22 (58) |
Not well | 4 (11) |
Had another treatment for their cancer | 10 (26) |
Takes a treatment for side effects related to previous cancer treatment | 8 (21) |
Takes a treatment for another condition | 21 (55) |
Feelings related to capecitabine | |
Advantages of the oral route, according to the patient | |
Autonomy | 22 (58) |
Less anxiety | 1 (3) |
Fewer side effects | 4 (11) |
No advantages | 3 (8) |
Disadvantages of the oral route, according to the patient | |
The lack of rigour in drug administration | 16 (42) |
Blood test | 2 (5) |
Loneliness | 2 (5) |
No disadvantages | 4 (11) |
Relationship with the oncologist | |
Explanations given by the oncologist about: | |
The treatment (organisation, administration) were insufficient | 1 (3) |
The treatment side effects occurrence were insufficient | 2 (5) |
Management of the treatment side effects were insufficient | 3 (8) |
Questions asked to the oncologist about the first prescription capecitabine | |
Side effects | 16 (42) |
Loss of hair | 2 (5) |
Efficacy | 2 (5) |
Treatment duration | 2 (5) |
Intention to obtain more information elsewhere | 13 (34) |
Other clinician | 3 (8) |
Internet | 10 (26) |
Expected changes in daily life due to capecitabine | |
Will have to be organised around the treatment administration | 26 (69) |
If side effects appear: | |
I will stop the treatment | 5 (13) |
I will consult a clinician | 23 (6A) |
I will continue the treatment whatever | 4 (10.5%) |
Opinions about adherence | |
I think that it is alright to miss a dose | 11 (28.9) |
I think that it is alright to stop voluntarily | 4 (10.5%) |
I think that missing a dose is dangerous | |
Yes | 16 (42.1%) |
Did not want to answer the question | 16 (42.1%) |
No | 6 (15.8%) |